CVRX CVRx, Inc.
CVRx, Inc. (CVRX) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.49 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.3% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About CVRx, Inc.
CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure.
Sector
Healthcare
Industry
Medical Appliances/Equipment